Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients with Pancreatic Adenocarcinoma Treated with SBRT

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 41, Issue 3, 2018, Pages 242-247

  Alagappan, Muthuraman ^a   Pollom, Erqi L ^a   Von Eyben, Rie ^a   Kozak, Margaret M ^a   Aggarwal, Sonya ^a   Poultsides, George A ^b   Koong, Albert C ^a   Chang, Daniel T ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

albumin; neutrophil lymphocyte ratio; pancreatic adenocarcinoma; SBRT

Indexed keywords

ALBUMIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GEMCITABINE; HEMOGLOBIN; SERUM ALBUMIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; ERYTHROCYTE COUNT; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEOADJUVANT CHEMOTHERAPY; NEUTROPHIL LYMPHOCYTE RATIO; NUTRITIONAL STATUS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PLATELET LYMPHOCYTE RATIO; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; ADENOCARCINOMA; BLOOD; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; MORTALITY; NEUTROPHIL; PANCREAS TUMOR; PROGNOSIS; RADIOSURGERY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; HUMANS; INFLAMMATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; NUTRITIONAL STATUS; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOSURGERY; RETROSPECTIVE STUDIES; SERUM ALBUMIN;

EID: 84954357244     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000263     Document Type: Article

References (53)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Society AC. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014.
3. Fortner JG, Klimstra DS, Senie RT, et al. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg. 1996;223:147-153.
4. Griffanti-Bartoli F, Arnone GB, Ceppa P, et al. Malignant tumors in the head of the pancreas and the periampullary region. Diagnostic and prognostic aspects. Anticancer Res. 1994;14(2B): 657-666.
5. Garcea G, Ladwa N, Neal CP, et al. Preoperative neutrophil-tolymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011;35:868-872.
6. Bhatti I, Peacock O, Lloyd G, et al. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200:197-203.
7. Smith RA, Bosonnet L, Raraty M, et al. Preoperative plateletlymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466-472.
8. Wang DS, Luo HY, Qiu MZ, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012;29:3092-3100.
9. McKay CJ, Glen P, McMillan DC. Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol. 2008;22: 65-73.
10. Martin HL, Ohara K, Kiberu A, et al. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Intern Med J. 2014;44:676-682.
11. Sugiura T, Uesaka K, Kanemoto H, et al. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after gastroenterostomy in patients with advanced pancreatic adenocarcinoma. Ann Surg Oncol. 2013;20:4330-4337.
12. Inoue D, Ozaka M, Matsuyama M, et al. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: A retrospective study in a single institute in Japan. Jpn J Clin Oncol. 2014;45:61-66.
13. An X, Ding PR, Li YH, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers. 2010;15:516-522.
14. Luo G, Guo M, Liu Z, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol. 2014;22:670-676.
15. Didolkar MS, Coleman CW, Brenner MJ, et al. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg. 2010;14: 1547-1559.
16. Mahadevan A, Jain S, Goldstein M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010;78:735-742.
17. Mahadevan A, Miksad R, Goldstein M, et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys. 2011;81:e615-e622.
18. Chuong MD, Springett GM, Freilich JM, et al. Stereotactic body radiation therapy for locally advanced and borderline resectablepancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013;86:516-522.
19. Rwigema JC, Parikh SD, Heron DE, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2011;34:63-69.
20. Goyal K, Einstein D, Ibarra RA, et al. Stereotactic body radiation therapy for nonresectable tumors of the pancreas. J Surg Res. 2012;174:319-325.
21. Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76:48-53.
22. Polistina F, Costantin G, Casamassima F, et al. Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010;17:2092-2101.
23. Pollom EL, Alagappan M, von Eyben R, et al. Single-versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Int J Radiat Oncol Biol Phys. 2014;90:918-925.
24. Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008;72:678-686.
25. Schellenberg D, Kim J, Christman-Skieller C, et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81:181-188.
26. Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58:1017-1021.
27. Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005; 63:320-323.
28. Herman JM, Chang DT, Goodman KA, et al. Phase 2 multiinstitutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2014;121:1128-1137.
29. Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009; 115:665-672.
30. Schweikard A, Shiomi H, Adler J. Respiration tracking in radiosurgery. Med Phys. 2004;31:2738-2741.
31. Minn AY, Koong AC, Chang DT. Stereotactic body radiation therapy for gastrointestinal malignancies. Front Radiat Ther Oncol. 2011;43:412-427.
32. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
33. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150SS.
34. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, et al. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012;23:265-273.
35. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc. 1999;94: 496-509.
36. Maretty-Nielsen K. Prognostic factors in soft tissue sarcoma. Dan Med J. 2014;61:B4957-B4967.
37. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436-444.
38. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102:5-14.
39. Aliustaoglu M, Bilici A, Seker M, et al. The association of pretreatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology. 2010;57:640-645.
40. Stotz M, Gerger A, Eisner F, et al. Increased neutrophillymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416-421.
41. Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283-287.
42. Romano F, Uggeri F, Crippa S, et al. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers. J Exp Clin Cancer Res. 2004;23:195-200.
43. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
44. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67:257-262.
45. Richards CH, Roxburgh CS, MacMillan MT, et al. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One. 2012;7:e41883.
46. Falconer JS, Fearon KC, Plester CE, et al. Cytokines, the acutephase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994;219:325-331.
47. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223-226.
48. Argilés JM, Busquets S, López-Soriano FJ. The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol. 2005;37:2036-2046.
49. Peng PD, van Vledder MG, Tsai S, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford). 2011;13:439-446.
50. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534-540.
51. Kabata P, Jastrzebski T, Kakol M, et al. Preoperative nutritional support in cancer patients with no clinical signs of malnutritionprospective randomized controlled trial. Support Care Cancer. 2014;23:365-370.
52. Ho VW, Leung K, Hsu A, et al. A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res. 2011;71:4484-4493.
53. Shin SJ, Yamada K, Sugisawa A, et al. Enhanced oxidative damage induced by total body irradiation in mice fed a low protein diet. Int J Radiat Biol. 2002;78:425-432.